Oppenheimer Research Analysts Lower Earnings Estimates for Tabula Rasa HealthCare Inc (NASDAQ:TRHC)

Tabula Rasa HealthCare Inc (NASDAQ:TRHC) – Equities research analysts at Oppenheimer decreased their Q1 2018 earnings per share (EPS) estimates for shares of Tabula Rasa HealthCare in a note issued to investors on Tuesday, March 13th, according to Zacks Investment Research. Oppenheimer analyst M. Naidu now expects that the company will earn ($0.06) per share for the quarter, down from their previous forecast of $0.02. Oppenheimer has a “Outperform” rating and a $47.00 price objective on the stock.

How to Become a New Pot Stock Millionaire

Tabula Rasa HealthCare (NASDAQ:TRHC) last posted its earnings results on Monday, March 12th. The company reported $0.09 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.12 by ($0.03). Tabula Rasa HealthCare had a negative return on equity of 1.96% and a net margin of 10.63%. The business had revenue of $43.93 million during the quarter, compared to analyst estimates of $38.91 million. During the same quarter in the prior year, the company earned $0.10 EPS. The company’s revenue was up 60.9% on a year-over-year basis.

Other equities research analysts have also issued research reports about the stock. Chardan Capital reiterated a “buy” rating and issued a $50.00 price objective (up previously from $46.00) on shares of Tabula Rasa HealthCare in a research note on Friday, March 16th. Citigroup assumed coverage on shares of Tabula Rasa HealthCare in a research report on Thursday, January 4th. They set a “buy” rating for the company. BidaskClub raised shares of Tabula Rasa HealthCare from a “hold” rating to a “buy” rating in a research report on Thursday, December 21st. Zacks Investment Research downgraded shares of Tabula Rasa HealthCare from a “buy” rating to a “hold” rating in a research report on Wednesday, March 7th. Finally, CIBC reissued an “outperform” rating and set a $47.00 target price (up from $35.00) on shares of Tabula Rasa HealthCare in a research report on Tuesday, March 13th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and eleven have issued a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $36.40.

Shares of TRHC traded up $0.24 on Friday, reaching $39.18. The company’s stock had a trading volume of 571,040 shares, compared to its average volume of 624,948. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.21 and a quick ratio of 1.11. Tabula Rasa HealthCare has a twelve month low of $11.59 and a twelve month high of $41.83. The firm has a market capitalization of $779.33, a PE ratio of -979.50, a P/E/G ratio of 8.65 and a beta of 2.39.

Institutional investors have recently bought and sold shares of the company. Wells Fargo & Company MN raised its position in Tabula Rasa HealthCare by 79.8% in the 3rd quarter. Wells Fargo & Company MN now owns 12,768 shares of the company’s stock worth $341,000 after purchasing an additional 5,668 shares during the period. JPMorgan Chase & Co. bought a new stake in Tabula Rasa HealthCare in the 3rd quarter worth $563,000. EAM Investors LLC grew its holdings in Tabula Rasa HealthCare by 21.5% in the 4th quarter. EAM Investors LLC now owns 178,588 shares of the company’s stock worth $5,009,000 after acquiring an additional 31,596 shares during the last quarter. Pier Capital LLC boosted its stake in shares of Tabula Rasa HealthCare by 33.3% during the 4th quarter. Pier Capital LLC now owns 206,905 shares of the company’s stock valued at $5,804,000 after purchasing an additional 51,673 shares in the last quarter. Finally, Vanguard Group Inc. boosted its stake in shares of Tabula Rasa HealthCare by 13.4% during the 2nd quarter. Vanguard Group Inc. now owns 236,964 shares of the company’s stock valued at $3,566,000 after purchasing an additional 27,997 shares in the last quarter. Hedge funds and other institutional investors own 47.28% of the company’s stock.

In other Tabula Rasa HealthCare news, CEO Calvin H. Knowlton sold 8,000 shares of the stock in a transaction that occurred on Monday, January 8th. The shares were sold at an average price of $32.75, for a total value of $262,000.00. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Bruce Luehrs sold 12,234 shares of the stock in a transaction that occurred on Tuesday, March 20th. The stock was sold at an average price of $38.01, for a total transaction of $465,014.34. The disclosure for this sale can be found here. Insiders have sold a total of 324,000 shares of company stock valued at $11,262,438 over the last three months. Insiders own 45.80% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Oppenheimer Research Analysts Lower Earnings Estimates for Tabula Rasa HealthCare Inc (NASDAQ:TRHC)” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another site, it was stolen and republished in violation of US and international copyright & trademark laws. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/07/oppenheimer-analysts-reduce-earnings-estimates-for-tabula-rasa-healthcare-inc-trhc.html.

Tabula Rasa HealthCare Company Profile

Tabula Rasa HealthCare, Inc (Tabula Rasa), formerly CareKinesis, Inc, is a provider of patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations and manage risk. The Company delivers its solutions through a suite of technology-enabled products and services for medication risk management, which includes bundled prescription fulfillment and adherence packaging services for client populations with complex prescription needs.

Get a free copy of the Zacks research report on Tabula Rasa HealthCare (TRHC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply